Founded nearly three decades ago, Arrhythmia Research Technology, Inc. (ART) has a broad portfolio of solutions and products that has been continually expanded over the years through the strategic acquisition and deployment of world class technologies, people and processes. The company has uniquely positioned itself to solve the design and manufacturing challenges virtually every industry’s design engineers and scientists face.
Through its wholly owned subsidiary Micron Products, Inc., ART manufactures silver plated and non-silver plated conductive resin sensors and distributes metal snaps used in the manufacture of disposable ECG, EEG, EMS and TENS electrodes. Micron’s MIT division manufactures custom injection molded products for medical, electronic, industrial and consumer applications, and provides high end mold design, manufacturing and precision machining for various industries.
ART’s other subsidiary, RMDDx Corp., is a development stage organization dedicated to the development and commercialization of medical devices, medical information technology, medical diagnostics and remote patient monitoring through wireless, internet and telecommunication technologies. The company also provides proprietary signal-averaging electrocardiography (SAECG) software used to detect potentially lethal heart arrhythmias.
Last month ART announced its financial results for the third quarter ended September 30, 2010. Revenue generated during the period equaled $5,888,000 and net income totaled $120,000, compared to total revenue of $5,457,000 and net income of $108,000 for the same quarter of 2009. For the nine month period ended September 30, 2010, total revenue increased by 11% while net income increased by 65% as compared to the same period in 2009.